JP2008527039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008527039A5 JP2008527039A5 JP2007552193A JP2007552193A JP2008527039A5 JP 2008527039 A5 JP2008527039 A5 JP 2008527039A5 JP 2007552193 A JP2007552193 A JP 2007552193A JP 2007552193 A JP2007552193 A JP 2007552193A JP 2008527039 A5 JP2008527039 A5 JP 2008527039A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000394 mitotic effect Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000020347 spindle assembly Effects 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- -1 3-amino-2- (R, S) -fluoropropyl Chemical group 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000007755 survival signaling Effects 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001672 cytoproliferative effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64490705P | 2005-01-19 | 2005-01-19 | |
| PCT/US2006/001365 WO2006078575A2 (en) | 2005-01-19 | 2006-01-13 | Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008527039A JP2008527039A (ja) | 2008-07-24 |
| JP2008527039A5 true JP2008527039A5 (US07794700-20100914-C00152.png) | 2009-02-26 |
Family
ID=36692759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552193A Withdrawn JP2008527039A (ja) | 2005-01-19 | 2006-01-13 | 有糸分裂キネシン阻害剤としてのフッ素化アミノアルキル−４−オキソ−３，４−ジヒドロピリド［３，４−ｄ］ピリジン |
Country Status (7)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2634445T3 (es) * | 2008-10-31 | 2017-09-27 | Janssen Biotech, Inc. | Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático |
| UY32922A (es) * | 2009-10-06 | 2011-04-29 | Bayer Schering Pharma Ag | Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265242A1 (en) * | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| CA2483627A1 (en) * | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US20050148593A1 (en) * | 2003-11-07 | 2005-07-07 | Gustave Bergnes | Compounds, compositions, and methods |
-
2006
- 2006-01-13 US US11/795,435 patent/US7632839B2/en not_active Expired - Fee Related
- 2006-01-13 CN CNA2006800025587A patent/CN101193637A/zh active Pending
- 2006-01-13 CA CA002595130A patent/CA2595130A1/en not_active Abandoned
- 2006-01-13 AU AU2006206652A patent/AU2006206652A1/en not_active Abandoned
- 2006-01-13 WO PCT/US2006/001365 patent/WO2006078575A2/en active Application Filing
- 2006-01-13 EP EP06718442A patent/EP1855664A4/en not_active Withdrawn
- 2006-01-13 JP JP2007552193A patent/JP2008527039A/ja not_active Withdrawn
